Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27523813 | 1.00 | TSHR (0.50) | TSHRMAPTABCC4ALDH1A1TRPA1 | |
| SCHEMBL16192560 | 1.00 | TSHR (0.50) | TSHRMAPTABCC4ALDH1A1TRPA1 | |
| SCHEMBL16192561 | 1.00 | TSHR (0.50) | TSHRMAPTABCC4ALDH1A1TRPA1 | |
| SCHEMBL25185208 | 1.00 | TSHR (0.50) | TSHRMAPTABCC4ALDH1A1TRPA1 | |
| SCHEMBL23493081 | 1.00 | TSHR (0.50) | TSHRMAPTABCC4ALDH1A1TRPA1 | |
| SCHEMBL23493083 | 1.00 | TSHR (0.50) | TSHRMAPTABCC4ALDH1A1TRPA1 | |
| SCHEMBL25182432 | 1.00 | TSHR (0.50) | TSHRMAPTABCC4ALDH1A1TRPA1 | |
| SCHEMBL25178927 | 1.00 | TSHR (0.50) | TSHRMAPTABCC4ALDH1A1TRPA1 | |
| SCHEMBL22553084 | 1.00 | TSHR (0.50) | TSHRMAPTABCC4ALDH1A1TRPA1 | |
| SCHEMBL5425721 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12031130-B2 | Composition for modifying target gene | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-09 | — | — | US | disclosed |
| US-11993570-B2 | Cationic lipids | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-28 | — | — | US | disclosed |
| EP-3733641-B1 | CATIONIC LIPIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-04-10 | — | — | EP | disclosed |
| CN-111511713-B | Cationic lipid | 武田药品工业株式会社 | 2024-01-02 | — | — | CN | disclosed |
| CN-111527204-B | Composition for target gene modification | 国立大学法人京都大学 | 2023-09-01 | — | — | CN | disclosed |
| US-20230257338-A1 | CATIONIC LIPIDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20210371854-A1 | COMPOSITION FOR MODIFYING TARGET GENE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-12-02 | — | — | US | disclosed |
| EP-3733641-A1 | CATIONIC LIPIDS | Takeda Pharmaceutical Company Limited (JP) | 2020-11-04 | — | — | EP | disclosed |
| EP-3733844-A1 | COMPOSITION FOR MODIFYING TARGET GENE | Kyoto University (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20200331841-A1 | CATIONIC LIPIDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-22 | — | — | US | disclosed |
| CN-1906183-B | N-acylsulfonamide apoptosis promoters | ABBOTT LAB | 2012-06-20 | — | — | CN | disclosed |
| US-4440940-A | HYPOLIPIDEMIC AND ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1984-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993570-B2 | Cationic lipids | ELOVL5, LPCAT3, ELOVL3 | TSHR 4055/4885MAPT 4656/4885ABCC4 2453/4885 |
| US-20210371854-A1 | COMPOSITION FOR MODIFYING TARGET GENE | NSUN2, NSUN3, RNASE1 | TSHR 3411/4885MAPT 4160/4885ABCC4 2884/4885 |
| US-12031130-B2 | Composition for modifying target gene | NSUN2, NSUN3, RNASE1 | TSHR 3411/4885MAPT 4160/4885ABCC4 2884/4885 |
| US-20230257338-A1 | CATIONIC LIPIDS | ELOVL5, LPCAT3, ELOVL3 | TSHR 4055/4885MAPT 4656/4885ABCC4 2453/4885 |
| US-20200331841-A1 | CATIONIC LIPIDS | ELOVL5, LPCAT3, ELOVL3 | TSHR 4055/4885MAPT 4656/4885ABCC4 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.